RxDoctor Payments Data

Aliya Safwan, MD

Internal Medicine · Watkinsville, GANPI 1306395520

Payments from drug & device makers

$2,092in general payments, 2019–2025

Across 110 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$454
  • AstraZeneca$238
  • Lilly USA, LLC$237
  • Exact Sciences$171
  • Boehringer Ingelheim$144
  • Pfizer$142
  • plus $707 from 12 others

What the payments were for

  • Food & beverage$2,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,092 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$83,326
Medicare patients
214
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$166,961
MounjaroTirzepatide97$138,347
RybelsusSemaglutide48$99,817
EliquisApixaban48$61,055
OzempicSemaglutide31$45,321
TrulicityDulaglutide16$31,212
JanuviaSitagliptin Phosphate23$30,149
XareltoRivaroxaban21$23,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,322
FarxigaDapagliflozin Propanediol12$13,987
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$12,049
Tresiba Flextouch U-100Insulin Degludec13$10,117
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$6,420
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,205
Atorvastatin Calcium633$5,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$237$169,559113 claims
Boehringer IngelheimJardiance$144$166,961129 claims
Novo NordiskRybelsus, Ozempic$454$145,13779 claims
PfizerEliquis$142$61,05548 claims
Johnson & JohnsonXarelto$101$23,25821 claims
GSKTrelegy Ellipta$72$16,32213 claims
AstraZenecaFarxiga$238$13,98712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →